Reducing fibrosis progression of biliary atresia by continuous administration of aducanumab at low dose: A potential treatment. (August 2022)

• Record Type: Journal Article
• Authors: Lyu, Hongyu; Ye, Yongqin; Chi Hang Lui, Vincent; Wang, Bin
• Is Part Of: Medical hypotheses. Volume 165(2022)
• Publication Date: 2022-08
• Subjects: Aβ beta-amyloid -- AgNps Silver nanoparticles -- ALP alkaline phosphatase -- APOE apolipoprotein E -- APP amyloid precursor protein -- APRi AST/platelet ratio index -- ARIA amyloid-related imaging abnormalities -- AST aspartate Transaminase -- BA biliary atresia -- BDP bile duct proliferation -- BEC biliary epithelial cells -- GCSF granulocyte colony stimulating factor -- GGT γ-glutamyl transpeptidase -- HSC Hematopoietic Stem Cell -- Iba-1-positive Ionized calcium-binding adaptor protein-1 -- KPE Kasai portoenterostomy -- Ly6G lymphocyte antigen 6 -- MMP7 Matrix Metalloproteinase 7 -- PET positron emission tomography -- PSEN1/2 Presenilin1/2 -- TBA serum total bile acids; Beta-amyloid -- Aducanumab -- Biliary atresia -- Liver fibrosis; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Medicine; Periodicals; 610
• DOI: 10.1016/j.mehy.2022.110901
• Languages: English
• ISSNs: 0306-9877

Abstract

Abstract: Biliary atresia (BA) is a disease in which the intra- and extrahepatic bile ducts are blocked, leading to cholestatic liver cirrhosis and liver failure. Kasai portoenterostomy (KPE) and liver transplantation are the gold treatment methods since effective medical interventions are lacking. Limited by the availability of early screening methods, children with biliary atresia are often not diagnosed in time, which has a negative impact on postoperative recovery. Beta-amyloid (Aβ) is the main pathological feature of Alzheimer's disease and is deposited in the liver tissue of biliary atresia. Aducanumab is the first targeted drug based on Alzheimer's pathogenesis that effectively reduces the load of Aβ. Thus, we hypothesized that low-dose aducanumab may be used for biliary atresia, which would slow down / prevent progressive liver cirrhosis in BA patients.